Meet Delic Corp, The Largest Ketamine Clinic Network in the U.S.
Similar Posts
Interview with Matt Zemon, Co-Founder, Psychable
In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.
![LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-35-600x338.jpeg)
LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]
Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
So make sure you stick around for both.
Timecodes:
0:00 – Intro
3:30 – New Phase 1 Clinical Trial
9:45 – Changes in Leadership
13:19 – New MindMed Partnership
20:30 – Conclusion
So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?
First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.
Why combine these two substances?
What diseases could it help alleviate?
And what is the timeline for this project?
Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.
Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.
Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.
Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.
Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
We talked about all sorts of interesting topics and I had a great time.
I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
https://www.instagram.com/sena__maria/
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
Spotlight Roundup-Another Psychedelic Company Lists On The Nasdaq
June 9, 2021- This week’s Psychedelic Business News top stories…
PharmaTher Files Patent on Ketamine for Diabetes and Obesity Treatment
Ketamine may be a useful treatment for diabetes and obesity, according to a new patent filed by psychedelic company PharmTher.
Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments
MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.
That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.
In this video, we will play the most important clips and offer some commentary where necessary.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
Top 5 Most Influential Psychedelic Studies
We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
Interview with Matt Zemon, Co-Founder, Psychable
In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.
LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]
Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
So make sure you stick around for both.
Timecodes:
0:00 – Intro
3:30 – New Phase 1 Clinical Trial
9:45 – Changes in Leadership
13:19 – New MindMed Partnership
20:30 – Conclusion
So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?
First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.
Why combine these two substances?
What diseases could it help alleviate?
And what is the timeline for this project?
Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.
Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.
Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.
Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.
Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
We talked about all sorts of interesting topics and I had a great time.
I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
https://www.instagram.com/sena__maria/
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
Spotlight Roundup-Another Psychedelic Company Lists On The Nasdaq
June 9, 2021- This week’s Psychedelic Business News top stories…
PharmaTher Files Patent on Ketamine for Diabetes and Obesity Treatment
Ketamine may be a useful treatment for diabetes and obesity, according to a new patent filed by psychedelic company PharmTher.
Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments
MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.
That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.
In this video, we will play the most important clips and offer some commentary where necessary.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
Top 5 Most Influential Psychedelic Studies
We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
Interview with Matt Zemon, Co-Founder, Psychable
In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.
LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]
Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
So make sure you stick around for both.
Timecodes:
0:00 – Intro
3:30 – New Phase 1 Clinical Trial
9:45 – Changes in Leadership
13:19 – New MindMed Partnership
20:30 – Conclusion
So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?
First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.
Why combine these two substances?
What diseases could it help alleviate?
And what is the timeline for this project?
Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.
Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.
Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.
Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.
Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
We talked about all sorts of interesting topics and I had a great time.
I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
https://www.instagram.com/sena__maria/
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
Spotlight Roundup-Another Psychedelic Company Lists On The Nasdaq
June 9, 2021- This week’s Psychedelic Business News top stories…
PharmaTher Files Patent on Ketamine for Diabetes and Obesity Treatment
Ketamine may be a useful treatment for diabetes and obesity, according to a new patent filed by psychedelic company PharmTher.
Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments
MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.
That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.
In this video, we will play the most important clips and offer some commentary where necessary.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
Top 5 Most Influential Psychedelic Studies
We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.